FDA supports first generic naloxone nasal spray to treat opioid overdose

Spread the love

The life-sparing medication that can stop or invert the impacts of an opioid overdose may counteract a huge number of passings.

Generic drugmaker Teva Pharmaceutical Industries Ltd on Friday received endorsement from the U.S. Food and Drug Administration (FDA) to showcase its generic nasal spray for opioid overdose, the health regulator said.

This is the first endorsement of a generic naloxone nasal spray for use in a community setting by individuals without medical training, the FDA said in an announcement.

Right around 400,000 individuals passed on from an opioid overdose from 1999 to 2017, the regulator stated, refering to information from the Centers for Disease Control and Prevention.

The FDA had tentatively affirmed Teva’s generic naloxone nasal spray in June a year ago.

Freida Dhanial